BioStock: Abliva’s CEO comments on the proposed capital raise

Abliva’s 2023 Year-End report focuses on the successful enrolment in December for Wave 1 of the phase II 'FALCON' study with lead candidate KL1333. Other key milestones include initiating dosing and receiving Fast Track Designation for the programme. BioStock contacted Abliva’s CEO Ellen Donnelly to learn more about the most impactful milestones achieved during the quarter and the recently announced rights issue that aims to support ongoing activities and provide additional runway.

Read the interview with Ellen Donnelly at biostock.se:

Abliva’s CEO comments on the proposed capital raise - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/